Stanford Medicine Children's Health, Stanford University, Stanford, California, USA.
Oregon Health and Science University, Portland, Oregon, USA.
Paediatr Anaesth. 2024 Dec;34(12):1200-1212. doi: 10.1111/pan.14983. Epub 2024 Sep 8.
Although direct oral anticoagulants (DOACs) have been used in the adult population for over a decade, DOACs use has begun to rise in pediatric populations since FDA approval of rivaroxaban and dabigatran, DOACs offer several advantages for pediatric patients, to other anticoagulants, including a similar safety profile, minimal lab monitoring, and ease of administration. The rise in DOAC use has led to an increasing number of pediatric patients managed on DOACs presenting for elective and urgent procedures. Perioperative management of anticoagulation is often challenging for providers due to the lack of expert consensus guidelines and the difficulty in balancing a patient's thrombotic risk with bleeding risk for a given procedure.
Using the most up to date literature, we provide a focused review on the perioperative management of DOACs in pediatric patients.
This work presents a focused review for pediatric anesthesiologists on clinically available DOACs, perioperative monitoring and management of DOACs, as well as options and indications for reversal. While consensus expert practice guidelines are still needed, we hope this work will familiarize perioperative physicians with these agents, recommended uses, and potential perioperative management.
尽管直接口服抗凝剂(DOACs)在成年人群中已经使用了十多年,但自 FDA 批准利伐沙班和达比加群以来,DOACs 在儿科人群中的使用开始增加,DOACs 为儿科患者提供了优于其他抗凝剂的优势,包括相似的安全性、最小的实验室监测和易于管理。DOAC 使用的增加导致越来越多的接受 DOAC 治疗的儿科患者因择期和紧急手术而接受治疗。由于缺乏专家共识指南以及难以平衡患者在特定手术中的血栓形成风险和出血风险,抗凝治疗的围手术期管理对提供者来说通常具有挑战性。
我们使用最新的文献,重点综述了儿科患者 DOAC 的围手术期管理。
这项工作为儿科麻醉师提供了关于临床可用的 DOAC、DOAC 的围手术期监测和管理以及逆转的选择和适应证的重点综述。虽然仍需要专家共识实践指南,但我们希望这项工作能使围手术期医生熟悉这些药物、推荐用途和潜在的围手术期管理。